-

11:14:25 PM

CNTB Stock News

CNTB - Connect Biopharma Holdings Ltd

05/17/22 4:05 PM

Nasdaq : CNTB

low float

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through

RHEA-AI

neutral

05/11/22 8:00 PM

Nasdaq : CNTB

managementclinical triallow float

CANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

CANbridge Pharmaceuticals, Inc., a China- based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that it has appointed Pauline Li, MD, to the position of Senior Vice President of Clinical Development and Operations,...

RHEA-AI

very positive

05/03/22 4:05 PM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement , but did not achieve statistical significance Clinical Remission on adapted Mayo Score and other secondary endpoints achieved statistical

RHEA-AI

neutral

03/31/22 4:05 PM

Nasdaq : CNTB

earningslow float

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline P ha se 2 CBP-307 Results in Mo d er a te-to- S evere Ulcerative Colitis Expected to Be Reported in H1 2022 - - C a sh B a l an c e o f RMB 1,706.9 million (U S D 267.7 milli o n) a

RHEA-AI

negative

03/01/22 8:00 AM

Nasdaq : CNTB

managementlow float

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma," “Connect,” or the

RHEA-AI

very positive

02/09/22 7:00 AM

Nasdaq : CNTB

conferenceslow float

Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the

RHEA-AI

neutral

01/24/22 7:00 AM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference

—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo —Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baseline

RHEA-AI

neutral

01/05/22 7:00 AM

Nasdaq : CNTB

clinical triallow float

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

—Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo— —Additional analyses demonstrate a potentially competitive therapeutic profile for CBP-201 300mg

RHEA-AI

neutral

01/04/22 4:05 PM

Nasdaq : CNTB

conferencesclinical triallow float

Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201

Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the

RHEA-AI

neutral

01/03/22 6:00 AM

Nasdaq : CTKB, CNTB, EXAS

Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics

The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenvironment activated therapeutic programs including bispecific...

RHEA-AI

positive

CNTB Data

IndustryResearch and Development in Biotechnology
Websitewww.connectbiopharm.com
Security nameConnect Biopharma Holdings Ltd - ADR
Issue typead
SectorProfessional, Scientific, and Technical Services
Sic code2834

About Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).